BR9809694A - Processo e composição para administração de taxanos oralmente a pacientes humanos - Google Patents

Processo e composição para administração de taxanos oralmente a pacientes humanos

Info

Publication number
BR9809694A
BR9809694A BR9809694-0A BR9809694A BR9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A
Authority
BR
Brazil
Prior art keywords
taxane
human patients
administered
oral
orally
Prior art date
Application number
BR9809694-0A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR9809694A publication Critical patent/BR9809694A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"PROCESSO E COMPOSIçãO PARA ADMINISTRAçãO DE TAXANOS ORALMENTE A PACIENTES HUMANOS"<D>. Agentes antineoplásticos de taxano que até aqui exibiram biodisponibilidade oral fraca ou não existente são administrados oralmente a pacientes humanos sofrendo de estados de doença em resposta a taxano e são tornados suficientemente biodisponíveis para atingir os níveis sang³íneos terapêuticos. Em uma modalidade preferida, o taxano, preferencialmente paclitaxel, é co-administrado ao paciente com um agente de melhoramento oral ciclosporina, preferencialmente ciclosporina A. Por um processo preferido, uma dose de melhorador oral é administrada a aproximadamente 0,5-72 horas antes do taxano e uma segunda dose do melhorador é administrada imediatamente antes, junto com ou imediatamente depois do taxano. é também fornecido um processo para tratar pacientes humanos sofrendo de estados de doença em resposta a taxano, assim como um processo para fornecer tal tratamento enquanto previne ou reduz a hipersensibilidade e as reações alérgicas sem a necessidade de pré-medicação.
BR9809694-0A 1997-05-27 1998-04-22 Processo e composição para administração de taxanos oralmente a pacientes humanos BR9809694A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
BR9809694A true BR9809694A (pt) 2000-10-03

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809694-0A BR9809694A (pt) 1997-05-27 1998-04-22 Processo e composição para administração de taxanos oralmente a pacientes humanos

Country Status (23)

Country Link
EP (1) EP0994706B1 (pt)
JP (1) JP2002500667A (pt)
KR (1) KR100615783B1 (pt)
CN (2) CN1550231A (pt)
AR (1) AR012731A1 (pt)
AT (1) ATE308365T1 (pt)
AU (1) AU7130098A (pt)
BR (1) BR9809694A (pt)
CA (1) CA2290446C (pt)
CZ (1) CZ9904244A3 (pt)
DE (1) DE69832173T2 (pt)
DK (1) DK0994706T3 (pt)
ES (1) ES2247690T3 (pt)
HK (1) HK1026637A1 (pt)
HU (1) HUP0003546A3 (pt)
IL (2) IL132992A0 (pt)
NO (1) NO995812L (pt)
PL (1) PL337064A1 (pt)
RU (1) RU2205005C2 (pt)
SK (1) SK157599A3 (pt)
UA (1) UA74767C2 (pt)
WO (1) WO1998053811A1 (pt)
ZA (1) ZA984268B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
ATE219363T1 (de) * 1997-06-20 2002-07-15 Baker Norton Pharma Lösliche prodrugs von paclitaxel
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ES2270834T3 (es) 1999-05-17 2007-04-16 Cancer Research Ventures Limited Composiciones para mejorar la biodisponibilidad de farmacos administrados oralmente.
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
JP2004520398A (ja) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ596868A (en) * 2009-06-02 2014-04-30 Nikan Pharmaceuticals Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4308114A1 (en) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
EP0494623A1 (en) * 1991-01-11 1992-07-15 Laboratoires Glaxo Sa Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2195844C (en) * 1994-07-26 2001-10-09 Ezio Bombardelli Semi-synthetic taxanes with anti-tumoural activity
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN100341485C (zh) * 1998-04-01 2007-10-10 斯凯伊药品加拿大公司 抗癌组合物

Also Published As

Publication number Publication date
SK157599A3 (en) 2002-10-08
IL132992A (en) 2006-08-20
RU2205005C2 (ru) 2003-05-27
KR20010013025A (ko) 2001-02-26
IL132992A0 (en) 2001-03-19
DK0994706T3 (da) 2006-03-06
UA74767C2 (en) 2006-02-15
HK1026637A1 (en) 2000-12-22
HUP0003546A3 (en) 2002-12-28
EP0994706A4 (en) 2001-05-16
ATE308365T1 (de) 2005-11-15
EP0994706B1 (en) 2005-11-02
PL337064A1 (en) 2000-07-31
WO1998053811A1 (en) 1998-12-03
EP0994706A1 (en) 2000-04-26
CZ9904244A3 (cs) 2001-10-17
AR012731A1 (es) 2000-11-08
KR100615783B1 (ko) 2006-08-25
AU7130098A (en) 1998-12-30
CA2290446A1 (en) 1998-12-03
ZA984268B (en) 1999-06-23
CN1261275A (zh) 2000-07-26
CN1550231A (zh) 2004-12-01
CA2290446C (en) 2008-01-29
ES2247690T3 (es) 2006-03-01
DE69832173T2 (de) 2006-08-03
DE69832173D1 (de) 2005-12-08
HUP0003546A2 (hu) 2002-11-28
NO995812D0 (no) 1999-11-26
JP2002500667A (ja) 2002-01-08
NO995812L (no) 2000-01-25

Similar Documents

Publication Publication Date Title
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
KR970061244A (ko) 치매 치료용 약학 조성물
Mannis et al. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
CA2519789A1 (en) Aplidine for multiple myeloma treatment
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1769 DE 20041130 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.